CDC's Rapid Surveys System questioned 8,118 US adults from two probability-based online panels in July–August 2025. Overall, 9.8% reported past-year GLP-1 use, rising from 8.1% with overweight to 24.1% with severe (class 3) obesity. Use was 47.4% among adults who had ever had diabetes, against 5.7% among those who had not. Among the 976 users, 22.6% took a compounded version, more often women (27.3%) than men (14.8%). Some 44% modified prescribed use, mostly by skipping doses (28%), with 54% at ages 18–39 and 30% at ≥65. Cumulative panel response rates were 13.3% and 3.8%, and all data were self-reported.
Why it is interesting: It gives a national survey estimate of GLP-1 uptake, including use of products not reviewed by the FDA. Cost was cited by 58% of modifiers aged 18–39, against 20% of those aged 65 and over.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.